ArticleAmerican journal of translational research2026
The role and mechanism of CHST6-mediated lactation modification in lenvatinib resistance in hepatocellular carcinoma cells.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is the 3rd leading cause of cancer-related death. Approximately 70% of HCC patients present with advanced-stage disease at the time of diagnosis. Lenvatinib is a standard first-line treatment for HCC; however, the development of drug resistance substantially limits its therapeutic efficacy.
methodsGenes associated with lactylation and lenvatinib resistance were identified through bioinformatic analyses. Differentially expressed genes (DEGs) were screened using data from the TCGA-LIHC cohort, the GSE186191 dataset, and a lactylation-related gene datasets. Receiver operating characteristic (ROC) curve analysis, Cox regression analysis, survival analysis, and prognostic evaluation were performed to analyze the association between identified genes and treatment outcomes. After constructing the lenvatinib-resistant MHCC97 cell line (MHCC97-LR) was established, and the effects of CHST6 knockdown on cell viability, apoptosis, cell cycle, lactate content, and the expression of lactylation-related genes were analyzed.
resultsA total of 15 overlapping DEGs related to both lactylation and lenvatinib resistance were identified. These genes were involved in multiple metabolic pathways, including lipid and glucose metabolism. CHST6, SPAG4, and PFKFB4 exhibited excellent diagnostic performance for HCC, and their lower expression levels were correlated with favorable prognosis. Cox regression analysis identified CHST6 as the only gene significantly associated with HCC prognosis, demonstrating predictive value for 1-5-year survival in HCC patients. Strikingly, enhanced lactylation was associated with elevated CHST6 expression and greater cell viability in MHCC97-LR cells. Furthermore, CHST6 knockdown reduced the lactate production and the expression of lactylation-associated proteins (Pan-Kla, H3K18la, and H3K56la) in MHCC97-LR cells, along with increased apoptosis and G1-phase cell-cycle arrest in MHCC97-LR cells.
conclusionCHST6 knockdown reduces intracellular lactate contents and lactylation in MHCC97-LR cells, thereby attenuating lenvatinib resistance and enhancing the antitumor efficacy of lenvatinib in HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.